Filing Flows › Sonoma Pharmaceuticals (SNOA) › Q3 FY25
Sonoma Pharmaceuticals (SNOA) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Feb 5, 2025
Sonoma Pharmaceuticals (SNOA) reported revenue of $3.6M for the third quarter fiscal 2025 (Q3 FY25), +14% from a year earlier and -0.4% from the quarter before. Operating margin was -28.9%, net loss $928K (26.0% of revenue).
Sonoma Pharmaceuticals, Q3 FY25: revenue $3.6M (+14% year over year), operating margin -28.9%, net loss $928K, operating cash flow $565K. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.6M | -0.4% | +14% |
| Operating profit | −$1.0M | — | — |
| Net earnings | −$928K | — | — |
| Operating cash flow | $565K | +60% | — |
| Free cash flow | $563K | +72% | — |
What changed
Revenue was $3.6M in Q3 FY25, up 14% year over year and roughly flat from the previous quarter.
Gross margin was 35.6%, down 10.9 points from a year earlier. Operating costs exceeded revenue by $1.0M, an operating margin of -28.9%. Operating expenses fell 0% while revenue rose 14%. The fastest-growing cost line was SG&A (+10%). The quarter ended with a net loss of $928K, wider than the previous quarter's $610K loss.
Operating cash flow was $565K. Non-cash charges added back $33K of depreciation and amortization and $13K of share-based compensation. Working capital and other items added $1.4M. Capital expenditures of $2K left free cash flow of $563K.
Questions
What was Sonoma Pharmaceuticals' revenue in the third quarter fiscal 2025?
Sonoma Pharmaceuticals (SNOA) reported revenue of $3.6M for the third quarter fiscal 2025 (Q3 FY25), +14% from a year earlier and -0.4% from the quarter before.
Was Sonoma Pharmaceuticals profitable in the third quarter fiscal 2025?
Operating loss was $1.0M (-28.9% of revenue) and net loss $928K.